July 26, 2017 5:39pm
… After yesterday’s low tide, “a rising market lifted some boats”
Short-term gain is still an algorithm tweak
Out and about: Pluristem Therapeutics (PSTI) jumped $0.02 to $1.22 on data from a clinical trial. The results, from a P2 simulated animal trial, focused on 12 PRIMATES and found that those PRIMATES had faster recovery in their white blood cell and platelet counts than a control group. My goodness +$0.02 is a JOKE if these results were that good – typical PSTI over-reaching HYPE!
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
Wednesday’s results have implications to Thursday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s investor’s newsletter, “What’s sustainable in this environment? A couple of primary and secondary efficacy endpoints misses in two days don’t help the sector … it’s still all about clinical results. Can another rising market tide lift some boats after the low tide beached many?”
- The battle of the oversold and the overbought continues but, who or what is making that determination – ETFs and algorithms.
Volume was still sluggish and all over the map; which seems higher in selling - again it is a gauge of how the sector feels at the moment.
- The sector breaks-up, reconnects but … expect the relationship to the upside to dwindle!
Investors are NOT engaged and traders are hedging while ETFs expose and algorithms are calculating … as 8/1 is soon to begin the Q2/17 results season of losses per share and their subsequent definitions.
Consider today – a one day WARNING … its coming!
- Say what, the next downside and then a tsunami …
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The first hour was positive with an A/DL of 23/14 and 6 flats;
· The mid-day was positive with an A/DL of 26/12 and 5 flats;
· The close was positive with an A/DL of 21/18 and 4 flats;
Out and about:
Pluristem Therapeutics (PSTI) jumped +$0.02 to $1.22 in extremely heavy afternoon trade Wednesday after the company released new data from a clinical trial. The results, from a P2-equivalent (animal) clinical trial, focused on 12 primates and found that those primates had faster recovery in their white blood cell and platelet counts than a control group.
PSTI's PLX-R18 therapy, intended as a treatment for a radiation syndrome … could possibly … be used for bone marrow deficiencies too, PSTI said. The study also strengthened the therapy's safety profile, suggesting it could be used in disaster scenarios on those affected without having to confirm that they have the radiation syndrome
... Three words, "watch your wallet" ...
Daily analytics:
U.S. stock-market indexes eked out modest gains, closing at all-time highs on Wednesday, after the Fed left interest rates unchanged and reaffirmed it will soon start reducing its $4.5 trillion balance sheet.
The main indexes were already trading higher before the announcement, driven by upbeat earnings results. The S&P 500 SPX (+0.03%) closed a fraction of a point higher at 2,477.83. The Dow (DJIA) gained 97.58 points, or 0.5%, to 21,711.01. The NASDAQ advanced 10.57 points, or 0.2%, to 6,422.75.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded at 9.60 on Wednesday following Tuesday’s near 9.43 – flat as compared to Monday’s 9.43 …
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Wednesday was down -0.57%
· Tuesday was up +0.89%
· Monday’s up +0.14%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Wednesday was up +0.65%
· Tuesday was down -1.08%
· Monday’s up +0.76%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %’s migrate……….
· Wednesday’s decliners ranged from -0.30% <XON> to -12.10% <CUR> in 18 equities;
· Tuesday’s decliners ranged from -0.10% <JUNO> to -49.64% <CUR> in 29 equities;
· Monday’s decliners ranged from -0.35% <BSTG> to -56.77% <CYTX> in 18 equities
Versus
………… look at the percentage’s (%) and their decreases …….
· Wednesday’s gainers ranged from +0.28% <VSTM> to +18.85% <ISCO> in 21 equities;
· Tuesday’s gainers ranged from +0.56% <XON> to +2.16% <NWBO> in 10 equities;
· Monday’s gainers ranged from +0.61% <ATHX> to +10.22% <NWBO> in 20 equities;
Some of MY working trend lines or indications:
… The greatest volume to the downside: IMUC, MDXG, CYTX, BSTG and CUR
… Upside volume was weighted to: NWBO, JUNO, KITE, CAPR and VCEL
… Biggest $ downside: CLLS, CUR, MDXG, OSIR and QURE
… Largest $ upside: ONCE, KITE, BLUE, RGNX and ISCO
… Flat: AST, RENE.L, ADVM and OPXA
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
